Arbutus Biopharma Corp
NASDAQ:ABUS
Arbutus Biopharma Corp
NASDAQ:ABUS
Price:
2.69 USD
-1.47%
Market Closed
Updated:
May 2, 2024
Arbutus Biopharma Corp
Operating Income
|
Arbutus Biopharma Corp
Operating Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Operating Income
-$78.1m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$8.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
See Also
What is Arbutus Biopharma Corp's Operating Income?
Operating Income
-78.1m
USD
-78.1m
USD
Based on the financial report for Dec 31, 2023, Arbutus Biopharma Corp's Operating Income amounts to -78.1m USD.
What is Arbutus Biopharma Corp's Operating Income growth rate?
Operating Income CAGR 10Y
-21%
-21%
Over the last year, the Operating Income growth was -19%. The average annual Operating Income growth rates for Arbutus Biopharma Corp have been -11% over the past three years , -2% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
